Research Analysts Set Expectations for Ardelyx Q3 Earnings

Ardelyx, Inc. (NASDAQ:ARDX) – Equities research analysts at HC Wainwright lowered their Q3 2025 EPS estimates for shares of Ardelyx in a report released on Friday, November 1st. HC Wainwright analyst E. Arce now expects that the biopharmaceutical company will post earnings per share of ($0.01) for the quarter, down from their prior forecast of $0.02. HC Wainwright currently has a “Buy” rating and a $11.00 price target on the stock. The consensus estimate for Ardelyx’s current full-year earnings is ($0.25) per share. HC Wainwright also issued estimates for Ardelyx’s Q4 2025 earnings at $0.01 EPS and FY2026 earnings at $0.58 EPS.

Several other research analysts have also recently weighed in on ARDX. StockNews.com upgraded shares of Ardelyx from a “sell” rating to a “hold” rating in a report on Wednesday, July 31st. Wedbush restated an “outperform” rating and issued a $11.00 price target on shares of Ardelyx in a report on Friday, August 2nd. Finally, Citigroup dropped their target price on Ardelyx from $12.00 to $10.00 and set a “buy” rating on the stock in a research report on Monday. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $11.33.

Ardelyx Price Performance

ARDX opened at $5.89 on Monday. The company has a fifty day simple moving average of $6.06 and a 200 day simple moving average of $6.32. The company has a quick ratio of 3.99, a current ratio of 4.21 and a debt-to-equity ratio of 0.68. The stock has a market cap of $1.39 billion, a P/E ratio of -19.63 and a beta of 0.92. Ardelyx has a 12 month low of $3.43 and a 12 month high of $10.13.

Insider Transactions at Ardelyx

In other Ardelyx news, insider David P. Rosenbaum sold 49,564 shares of Ardelyx stock in a transaction dated Friday, September 27th. The stock was sold at an average price of $6.92, for a total transaction of $342,982.88. Following the transaction, the insider now directly owns 301,946 shares of the company’s stock, valued at approximately $2,089,466.32. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, insider David P. Rosenbaum sold 49,564 shares of the business’s stock in a transaction on Friday, September 27th. The shares were sold at an average price of $6.92, for a total value of $342,982.88. Following the transaction, the insider now owns 301,946 shares in the company, valued at $2,089,466.32. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Michael Raab sold 25,000 shares of Ardelyx stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $5.91, for a total value of $147,750.00. Following the completion of the transaction, the chief executive officer now directly owns 1,210,108 shares of the company’s stock, valued at approximately $7,151,738.28. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 212,126 shares of company stock valued at $1,298,963. 5.90% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Nisa Investment Advisors LLC lifted its position in Ardelyx by 1,026.3% in the 2nd quarter. Nisa Investment Advisors LLC now owns 3,548 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 3,233 shares in the last quarter. Redwood Wealth Management Group LLC bought a new position in shares of Ardelyx in the second quarter valued at approximately $62,000. Coastal Bridge Advisors LLC purchased a new position in shares of Ardelyx during the second quarter valued at approximately $74,000. Helen Stephens Group LLC bought a new stake in Ardelyx during the third quarter worth $76,000. Finally, Paloma Partners Management Co purchased a new stake in Ardelyx in the 1st quarter valued at $86,000. 58.92% of the stock is owned by institutional investors.

Ardelyx Company Profile

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.